 Cabaletta Bio Incs NASDAQ: CABA DSG3-CAART fails to show biologic activity to date in the two lowest cell dose cohorts of Phase 1 trial mucosal Pemphigus Vulgaris mPV. In cohort A1 20 million DSG3-CAART cells, two of three participants had DSG3 autoantibody levels that rose over 20, along with disease activity scores that worsened within six months after DSG3-CAART infusion. 